Please turn JavaScript on

Drug Discovery and Development

Receive updates from Drug Discovery and Development for free, starting right now.

We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.

This way you won't miss any new article from Drug Discovery and Development. Unsubscribe at any time.

Site title: Drug Discovery & Development | Pharma and Biotech Insights

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.65 / day

Message History

In traditional drug discovery, typical timelines for successful drugs stretch from 10 to 15 years, or sometimes even longer, to bring a drug from discovery to approval. In addition to that, the cost of bringing a drug to market can range from hundreds of millions to multiple billions of dollars. In fact, the inflation-adjusted cost…

The post


Read full story

A team from ETH Zurich and Karolinska Institutet has developed a cross-linking MALDI mass spectrometry workflow that captures both functional response and target binding in a single assay.  Drug screening has traditionally been split between functional assays and binding assays. However, neither tells the full story. Functional assays indicate whether a drug works, but n...


Read full story

Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase 2 trial in China, the company announced on Tuesday. UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G) and is being jointly developed with United Biotechnology.  The trial was conducted by…

The post


Read full story

Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to tirzepatide, the company announced on Monday. CagriSema, a combination of cagrilintide and semaglutide, achieved 23% weight loss after 84 weeks of treatment, compared to 25.5% with tirzepatide. The treatment was safe and well tolerated, with mostly ...


Read full story

Sai Life Sciences announced plans to hire more than 700 scientific, technical, and management professionals during 2026–27, citing growing global demand for integrated drug discovery, development, and manufacturing services. The Hyderabad-based CRDMO said the recruitment will span medicinal chemistry, biology, DMPK, process and analytical development, formulation development,...


Read full story